drugset / Trial / NCT00699140
Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.
Timeline
- Start
- 2008-02
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IGIV3I Grifols | Protein / enzyme biologic | 2 g/kg | Intravenous |